Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies

Lancet

Volumn 360, Issue 9327, 2002, Pages 119-129

  Egger, Matthias ^a   May, Margaret ^b   Chêne, Geneviève ^c   Phillips, Andrew N ^d   Ledergerber, Bruno ^e   Dabis, François ^c   Costagliola, Dominique ^f   D'Arminio Monforte, Antonella ^g   De Wolf, Frank ^i,j   Reiss, Peter ^h   Lundgren, Jens D ^k   Justice, Amy C ^l   Staszewski, Schlomo ^m   Leport, Catherine ⁿ   Hogg, Robert S ^o   Sabin, Caroline A ^d   Gill, M John ^p   Salzberger, Bernd ^q   Sterne, Jonathan A C ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c INSERM   (France)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f Section of Radiology   (France)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ STICHTING HIV MONITORING   (Netherlands)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k HVIDOVRE HOSPITAL   (Denmark)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m GOETHE UNIVERSITY   (Germany)

ⁿ BICHAT HOSPITAL   (France)

^o BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^p UNIVERSITY OF CALGARY   (Canada)

^q UNIVERSITY HOSPITAL REGENSBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGE; ARTICLE; CELL ASSAY; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; FRANCE; HAZARD ASSESSMENT; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; SWITZERLAND; TIME; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 0037072066     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09411-4     Document Type: Article

References (49)

1. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
2. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. Community-based approaches to HIV treatment in resource-poor settings
5. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
6. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis
7. CD4 cell count as a surrogate endpoint in HIV clinical trials: A meta-analysis of studies of the AIDS Clinical Trials Group
8. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
9. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
10. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
11. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
12. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients
13. Zidovudine and stavudine sequencing in HIV treatment planning: Findings from the CHORUS HIV cohort
14. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
15. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen
16. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: The Aquitaine cohort, 1996-1997
17. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine
18. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
19. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
20. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
21. Flexible alternatives to the Cox model
22. A new look at the statistical model identification
23. Bayesian measures of model complexity and fit
24. Assessing the generalizability of prognostic information
25. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errorsp
26. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study
27. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study
28. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy
29. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma
30. Association of cancer with AIDS-related immunosuppression in adults
31. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
32. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
33. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
34. More rapid progression to AIDS in older HIV-infected people: The role of CD4+ T-cell counts
35. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study
36. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study
37. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users
38. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program
39. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
40. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998
41. Impact of opportunistic disease on survival in patients with HIV infection
42. Gender differences in virologic response to treatment in an HIV-positive population: A cohort study
43. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
44. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
45. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
46. Immune restoration with antiretroviral therapies: Implications for clinical management
47. Hit HIV-1 hard, but only when necessary
48. Highly active antiretroviral therapy and coronary heart disease: The need for perspective
49. The need for randomization in the study of intended effects